Guardant Health (GH) is back in focus after new data on its Shield blood test for colorectal cancer screening and Guardant Reveal test for melanoma residual disease were released in October 2026.
Investors have taken notice of this Shield and Guardant Reveal data, even as the Guardant Health share price has eased in the short term. The 1-month share price return is down 9.32% and the 7-day share price return is down 5.30%. At the same time, the 1-year total shareholder return of 142.29% and the very large 3-year total shareholder return suggest momentum has already been strong. Recent weakness may reflect shifting views on risk and expectations around how quickly these tests translate into revenue.
Scan beyond Guardant Health and see how it compares with 33 healthcare AI stocks, which are also tying real-world clinical data to blood-based testing and cancer detection breakthroughs.
Guardant Health has surged over the past year even as the share price has recently pulled back. Does that dip leave enough potential upside to still justify the risk on today’s valuation tags?
Most Popular Narrative: 20.3% Undervalued
The most followed narrative pegs Guardant Health’s fair value at $199.04, compared with the recent $158.60 close, so the gap between price and story is wide. That spread rests heavily on how quickly blood-based cancer testing scales and how long strong volume trends can be maintained.
Accelerating adoption of non-invasive blood-based cancer diagnostics is driving substantial growth across Guardant Health’s key product lines (Guardant360 Liquid, Reveal, and Shield). This is expanding the company’s total addressable market and supporting high double-digit revenue growth, with continued strong volume momentum and share gains documented for both new and established oncology applications.
See why 22 investors see Guardant Health as 20% undervalued.
Result: Fair Value of $199.04 (UNDERVALUED)
Still, the bullish Guardant Health story could be knocked off course if heavy spending keeps cash burn high, or if payer coverage and reimbursement progress stalls.
Find out about the key risks to this Guardant Health narrative.
Another View: Guardant Health Looks Expensive On Sales
The SWS DCF model points to Guardant Health trading at a discount to estimated future cash flows, with a fair value of $215.49 against the recent $158.60 price. On that lens it screens as undervalued. The open question is whether those long range cash flow forecasts feel comfortable to you.
On simple sales-based metrics the picture flips. Guardant Health trades on a P/S ratio of 18x, while US Healthcare peers sit around 1.3x and the fair ratio is flagged at 9.7x. That is a wide gap. It raises the issue of whether investors are being paid enough for the valuation risk at today’s levels. See what the numbers say about this price — find out in our valuation breakdown.
Source: finance.yahoo.com
